Donald C. Moore

1.4k total citations
80 papers, 750 citations indexed

About

Donald C. Moore is a scholar working on Oncology, Hematology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Donald C. Moore has authored 80 papers receiving a total of 750 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 30 papers in Hematology and 17 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Donald C. Moore's work include Chronic Lymphocytic Leukemia Research (12 papers), Platelet Disorders and Treatments (12 papers) and Multiple Myeloma Research and Treatments (10 papers). Donald C. Moore is often cited by papers focused on Chronic Lymphocytic Leukemia Research (12 papers), Platelet Disorders and Treatments (12 papers) and Multiple Myeloma Research and Treatments (10 papers). Donald C. Moore collaborates with scholars based in United States, United Kingdom and Canada. Donald C. Moore's co-authors include Justin Arnall, Walter J. Hannah, Alaa Muslimani, Eric K. Singhi, Jai N. Patel, Steven Park, Alastair Greystoke, Malcolm Ranson, Caroline Dive and Andrew Hughes and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Donald C. Moore

72 papers receiving 737 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Donald C. Moore United States 13 276 206 144 141 99 80 750
Shiyu Xiao China 15 192 0.7× 219 1.1× 50 0.3× 138 1.0× 57 0.6× 33 846
Donald R. Fleming United States 13 345 1.3× 196 1.0× 123 0.9× 65 0.5× 71 0.7× 25 740
Martine George United States 9 277 1.0× 120 0.6× 179 1.2× 298 2.1× 64 0.6× 16 898
Thomas Robert France 15 243 0.9× 478 2.3× 117 0.8× 140 1.0× 45 0.5× 59 1.1k
Haruo Miwa Japan 16 296 1.1× 545 2.6× 214 1.5× 191 1.4× 21 0.2× 79 1.1k
Nael M. Mostafa United States 17 197 0.7× 151 0.7× 74 0.5× 54 0.4× 56 0.6× 54 957
P Stiehl Germany 13 200 0.7× 304 1.5× 43 0.3× 102 0.7× 42 0.4× 25 986
Elona Juozaitytė Lithuania 17 397 1.4× 169 0.8× 40 0.3× 143 1.0× 32 0.3× 86 842
Davide Lombardi Italy 17 609 2.2× 210 1.0× 26 0.2× 308 2.2× 69 0.7× 57 1.0k
Peter Kozuch United States 19 557 2.0× 259 1.3× 176 1.2× 263 1.9× 119 1.2× 42 1.1k

Countries citing papers authored by Donald C. Moore

Since Specialization
Citations

This map shows the geographic impact of Donald C. Moore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donald C. Moore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donald C. Moore more than expected).

Fields of papers citing papers by Donald C. Moore

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donald C. Moore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donald C. Moore. The network helps show where Donald C. Moore may publish in the future.

Co-authorship network of co-authors of Donald C. Moore

This figure shows the co-authorship network connecting the top 25 collaborators of Donald C. Moore. A scholar is included among the top collaborators of Donald C. Moore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donald C. Moore. Donald C. Moore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chan, Alexandre, William L. Baker, Daniel Abazia, et al.. (2025). Impact of artificial intelligence on future clinical pharmacy research and scholarship. JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. 8(4). 311–316. 2 indexed citations
2.
Moore, Donald C., et al.. (2025). Rilzabrutinib and Bruton tyrosine kinase inhibition for the treatment of persistent or chronic immune thrombocytopenia. Expert Opinion on Pharmacotherapy. 26(14-15). 1583–1588. 1 indexed citations
3.
Davis, James, Donald C. Moore, Charlotte B Wagner, et al.. (2024). Dexamethasone for the Management of CRS Related to Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 144(Supplement 1). 2382–2382. 1 indexed citations
4.
Loop, Matthew Shane, et al.. (2024). Oncology stewardship practice in the United States: A Hematology/Oncology Pharmacy Association national survey. Journal of Oncology Pharmacy Practice. 31(4). 517–527. 1 indexed citations
5.
6.
Moore, Donald C., et al.. (2024). Professional and career development needs of clinical pharmacists in settings outside academia. JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. 7(4). 402–407.
7.
Morris, Sarah, Alicia Hamilton, Nury Steuerwald, et al.. (2024). Real-World Impact of an In-House Dihydropyrimidine Dehydrogenase (DPYD) Genotype Test on Fluoropyrimidine Dosing, Toxicities, and Hospitalizations at a Multisite Cancer Center. JCO Precision Oncology. 8(8). e2300623–e2300623. 9 indexed citations
8.
Moore, Donald C., et al.. (2024). PD-1/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review. International Immunopharmacology. 129. 111606–111606. 20 indexed citations
9.
Patel, Jai N., Sarah Morris, Alicia Hamilton, et al.. (2023). Real-world experience of an in-house dihydropyrimidine dehydrogenase (DPYD) genotype test to guide fluoropyrimidine (FP) dosing at a multisite cancer hospital.. Journal of Clinical Oncology. 41(16_suppl). 1534–1534. 1 indexed citations
10.
Moore, Donald C., et al.. (2023). Hepatitis B reactivation in patients with multiple myeloma treated with anti-CD38 monoclonal antibody-based therapies: a pharmacovigilance analysis. International Journal of Clinical Pharmacy. 45(6). 1492–1495. 3 indexed citations
11.
Moore, Donald C., et al.. (2023). Revolutionizing Cancer Treatment: Harnessing the Power of Biomarkers to Improve Patient Outcomes. Journal of the Advanced Practitioner in Oncology. 14(3). 4–8. 9 indexed citations
12.
Tran, Thuy, et al.. (2022). Avatrombopag for the Treatment of Immune Thrombocytopenia and Periprocedural Thrombocytopenia Associated With Chronic Liver Disease. Journal of Pharmacy Practice. 37(1). 184–189. 3 indexed citations
13.
Moore, Donald C., et al.. (2021). A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies. Journal of the Advanced Practitioner in Oncology. 12(4). 439–447. 10 indexed citations
14.
Crawford, Jeffrey, Donald C. Moore, Vicki A. Morrison, & David C. Dale. (2021). Use of prophylactic pegfilgrastim for chemotherapy-induced neutropenia in the US: A review of adherence to present guidelines for usage. Cancer Treatment and Research Communications. 29. 100466–100466. 5 indexed citations
15.
Moore, Donald C., Justin Arnall, Barry Paul, et al.. (2020). Evaluation of Montelukast for the Prevention of Infusion-related Reactions With Daratumumab. Clinical Lymphoma Myeloma & Leukemia. 20(10). e777–e781. 10 indexed citations
16.
Tran, Thuy, et al.. (2020). Vonicog alfa for the management of von Willebrand disease: a comprehensive review and single-center experience. Journal of Thrombosis and Thrombolysis. 49(3). 431–440. 10 indexed citations
17.
Moore, Donald C., et al.. (2020). Dialysis Independence Following Combination Daratumumab, Thalidomide, Bortezomib, Cyclophosphamide, and Dexamethasone in Multiple Myeloma With Severe Renal Failure. Clinical Lymphoma Myeloma & Leukemia. 20(7). e395–e398. 4 indexed citations
18.
Moore, Donald C., et al.. (2019). Impact of Body Mass Index on the Incidence of Bortezomib-induced Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 20(3). 168–173. 6 indexed citations
19.
Moore, Donald C., et al.. (2018). Poly (ADP-ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: A Drug Class Review. Europe PMC (PubMed Central). 6 indexed citations
20.
Greystoke, Alastair, G. W. Harris, Martin Jenkins, et al.. (2013). Assessment of diurnal changes and confounding factors that affect circulating cell death biomarker levels: A short communication. Journal of Pharmaceutical and Biomedical Analysis. 84. 184–188. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shiyu Xiao Breakdown of academic impact, for papers by Donald R. Fleming Breakdown of academic impact, for papers by Martine George Breakdown of academic impact, for papers by Thomas Robert Breakdown of academic impact, for papers by Haruo Miwa Breakdown of academic impact, for papers by Nael M. Mostafa Breakdown of academic impact, for papers by P Stiehl Breakdown of academic impact, for papers by Elona Juozaitytė Breakdown of academic impact, for papers by Davide Lombardi Breakdown of academic impact, for papers by Peter Kozuch
Rankless by CCL
2026